Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

Aclidinium bromide is a long-acting muscarinic antagonistic used in maintenance treatment of chronic obstructive pulmonary disease (COPD). A model-based health economic study evaluated the cost-effectiveness of aclidinium 400 μg bid as an alternative to tiotropium 18 μg od for this indication in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ClinicoEconomics and outcomes research 2014-01, Vol.6 (default), p.175-185
Hauptverfasser: Karabis, Andreas, Mocarski, Michelle, Eijgelshoven, Indra, Bergman, Gert
Format: Artikel
Sprache:eng
Schlagworte:
Aclidinium bromide
Bronchitis
Chronic obstructive pulmonary disease
Cost analysis
Dosage and administration
Drug therapy
Economic aspects
Health care expenditures
Health care policy
Hospitals
Lung diseases, Obstructive
Medical economics
Medical research
Medicine, Experimental
Mortality
Original Research
Patients
Quality of life
Questionnaires
Respiratory diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aclidinium bromide is a long-acting muscarinic antagonistic used in maintenance treatment of chronic obstructive pulmonary disease (COPD). A model-based health economic study evaluated the cost-effectiveness of aclidinium 400 μg bid as an alternative to tiotropium 18 μg od for this indication in the US. PATIENT CHARACTERISTICS IN THIS MODEL REFLECT THOSE IN THE ACLIDINIUM CLINICAL STUDIES: age >40 years, stable moderate-to-severe COPD, current or ex-smokers (>10 pack-years), post-salbutamol forced expiratory volume in 1 second (FEV1) ≥30% and
ISSN:1178-6981
1178-6981
DOI:10.2147/CEOR.S57904